128300-09-4Relevant articles and documents
CYTOTOXIC AGENTS
-
, (2022/02/09)
The present invention provides a compound of formula (I): (T-X4)p-B1-X3-A-X2-L-X1-AM or pharmaceutically acceptable salts, tautomers, stereoisomers or mixtures thereof; wherein AM is (AM1); (AM2); or (AM3); with the proviso that the compound of formula (I) contains at least one sigma hole group; and with the proviso that no more than one of A, B1 and T is a sigma hole group; and each sigma hole group is independently: (SH1); (SH2); (SH3); (SH4); (SH5); (SH6); (SH7); (SH8); (SH9); or (SH10).
Synthesis, biological evaluation, and live cell imaging of novel fluorescent duocarmycin analogs
Tietze, Lutz F.,Behrendt, Frank,Pestel, Galina F.,Schuberth, Ingrid,Mitkovski, Mi?o
, p. 2559 - 2570 (2013/01/16)
For a better understanding of the mode of action of duocarmycin and its analogs, the novel fluorescent duocarmycin derivatives 13-15 and 17b-19b were synthesized, and their bioactivity as well as their cellular uptake investigated using confocal laser sca
Resolution of a CBI precursor and incorporation into the synthesis of (+)-CBI, (+)-CBI-CDPI1, (+)-CBI-CDPI2: Enhanced functional analogs of (+)-CC-1065. A critical appraisal of a proposed relationship between electrophile reactivity,
Boger,Ishizaki
, p. 793 - 796 (2007/10/02)
Details of the resolution of an immediate CBI precursor, (+)- and (-)-8, and its subsequent incorporation into (+)- and (-)-CBI-CDPI(n), optically-active enhanced functional analogs of (+)-CC-1065, are described. In marked contrast to a previously detaile